Current treatment strategies for patients with cancers of the head and neck;Současné strategie léčby karcinomů ORL oblasti

Klinicka Onkologie

Volumn 21, Issue 2, 2008, Pages 45-52

  Mechl, Zdeněk ^a,c   Smilek, P ^b   Cervena R ^a  

^a Odd lení Klinické a Radia ní Onkologie

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^c NONE   (Czech Republic)

Author keywords

Chemotherapy; Disease management; EGFR receptor inhibitors; Head and neck cancer; Radiotherapy; Surgery

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; BLEOMYCIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GEFITINIB; LAPATINIB; METHOTREXATE; PACLITAXEL;

BIOLOGY; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER THERAPY; CLINICAL STUDY; HEAD AND NECK CANCER; HISTOLOGY; HUMAN; REVIEW; SQUAMOUS CELL CARCINOMA; HEAD AND NECK TUMOR;

CARCINOMA, SQUAMOUS CELL; HUMANS; OTORHINOLARYNGOLOGIC NEOPLASMS;

EID: 42249090337     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Canellos GP. Clinical Oncology: Onward and Upward. J Clin Oncol 2008; 26: 2.
2. Grandis JR. Advances in the Medical Management of Patients With Head and Neck Cancer. New Engl J Med 2007; 357:17, 1695-1704.
3. Gralow J, Ozols RF, Bajorin DF. Clinical Cancer Advances 2007: Major Research Society of Clinical Oncology. JCO 2008; 26:2, 1-12.
4. Neuwirthová J. Etiologie maligních nádorů hlavy a krku. EUNI 2007: Nádory hlavy a krku, 2-3.
5. Posner MR. Epidemiology, Outcomes and Conventional Treatment Options for Patients With Cancer of the Head and Neck. CME 2007: Advances in the Treatment of Cancer of the Head and Neck.
6. Lefebre JL. Current issues and future therapy options for the treatment of head and neck cancer. Oncol Biotherapeutics 2001; 1:3, 2-23.
7. Smilek P. Chirurgická léčba karcinomů hlavy a krku.. In: Mechl Z, Smilek P, Neuwirthová J, et al. Maligní nádory hlavy a krku. Pears Health Cyber, EUNI, 2007.
8. Lefebre JL, Chevalier D, Luboinski B, et al. Is laryngeal preservation with induction chemotherapy safe in the treatment of hypofaryngeal SCC? Final results of the phase III EORTC 24891 trial. Proc ASCO 2004; 22 : 14, 5531.
9. Šlampa P. et al. Zhoubné nádory hlavy a krku. Radiační onkologie v praxi II edit, 2007; 18-33.
10. Burkoň P. IMRT - Radioterapie s modulovanou intenzitou. Farmakoterapie 2008; v tisku.
11. Šlampa P. Přehled konkomitantní chemoradioterapie solidních nádorů. Čas Lék čes. 2003; 142 (Suppl 1): 4-8.
12. Domenge C, Marandas P, Vignoud J, et al. Post-surgical adjuvant chemotherapy in extracapsular spread invaded lymph node of epidermoid carcinoma of the head and neck. Second International Conference on Head and Neck Cancer. Boston 1988; Abst 74.
13. Cooper JS, Pajak TF, Forastiere AA, et al.Postoperative concurrent radiotherapy and chemotherapy for high risk squamous-cell carcinoma of the head an neck. N Engl J Med 2004; 350: 1937-1944.
14. Fountzillas G, Ciuleanu E, Dafni E, et al. Concomitant radiochemotherapy vs. radiotherapy alone in patients with head and neck cancer. Med Oncol 2004; 21 ,1: 95-108.
15. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16: 1310-1417.
16. Vermorken JB, Remenar E, Carla van Herpen et al. Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer. N Engl J Med 2007; 357: 17,1695-1704.
17. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and Fluorouracil Alone or With Docetaxel in Head and Neck Cancer. N Engl J Med 2007; 357: 17, 1705-1715.
18. Grandis JR. Integrating Novel Therapies With Standard Modalities in the Treatment of Head and Neck Cancer. CME 2006.
19. Bonner JAS, Harari PM, Goraly J et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head aed neck. N Engl J Med 2006; 354: 567-678.
20. Cohen EEW. Novel Therapeutic Targets in Squamous Cell Carcinoma of the Head and Neck. Sem Oncol 2005: 31: 6: 755-769.
21. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C255 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinoma of the head and neck. Cancer Res 1999; 549:1935-1940.
22. Bernier JK, Schneider D. Cetuximab combined with radiotherapy. An alternative. To chemoradioterapy for patiens with locally advanced squamous cell carcinoma of the head and neck. EJC 2007; 43 : 6-29.
23. Neuwirthová J, Mechl Z, Smilek P et al. Integrace nových biologických přípravků do léčby spinocelulárních karcinomů hlavy a krku. Remedia 2007; 17: 181-187.
24. Jeremic B, Shibamoto Y, Milikcic B et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2000; 128: 1458-1464.
25. Vermorken J, Trigo J, Hitt R et al. Opel-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25: 16, 2171-2177.
26. Vermorken J, Mesia R, Vega V et al. Cetuximab extends survival of patiens with recurrent or metastatic HNSCC when added to first line platinum-based therapy. Results of a randomized phase III study (EXTREME). Proc ASCO 2007; Abst 609.
27. Bernier J. Current Treatment Approaches for Head and NeckCancer: Benefits, Limitations and Unmet Needs. CME 2007.